FrancophonIA/ELRC3.0 huggingface dataset:
English: Adverse drug reactions identified during the post-marketing experience with Caelyx Neoplasms benign, malignant and unspecified (incl cysts and polyps) very rare secondary oral neoplasms
Maltese: Neoplażmi beninni, malinni u dawk mhux speċifikati (li jinkludu ċesti u polipi) rari ħafna neoplażmi orali sekondarji
English: Reduce next dose by 25%.
Maltese: Naqqas id-doża li jmiss b'25 %.
English: PLATELETS
Maltese: LISTA
English: - For treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.
Maltese: - Trattament għall-kanċer avvanzat tal-ovarji f'nisa li jkunu fallew l-kura preferita bi programm ta' kura kemoterapewtika bbażata fuq il-platinum.
English: Vesiculobullous rash, pruritus, exfoliative dermatitis, skin disorder, maculopapular rash, sweating, acne, skin ulcer
Maltese: Raxx b'infafet u materja, ħakk, dermatite bi tqaxxir, mard tal-ġilda, raxx makulopapulari, għaraq, akne, ulċera talġilda
English: For doses < 90 mg, dilute Caelyx in 250 ml, and for doses  90 mg, dilute Caelyx in 500 ml.
Maltese: Għal dożi < 90 mg iddilwixxi Caelyx f'250 ml u għal dożi ≥ 90 mg, iddilwixxi Caelyx f'500 ml.
English: Although local necrosis following extravasation has been reported very rarely, Caelyx is considered to be an irritant.
Maltese: Għalkemm in-nekrożi lokali wara ekstravażazzjoni ġiet irrappurtat rarament ħafna, Caelyx jitqies bħala irritanti.
English: How to store Caelyx
Maltese: Kemm ser jingħata Caelyx
English: A similar low incidence of myelosuppression was seen in patients with metastatic breast cancer receiving Caelyx in a first-line clinical trial.
Maltese: Inċidenza baxxa simili ta' majelosoppressjoni nstabet f'pazjenti b'kanċer tas-sider metastatiku li ngħataw Caelyx bħala l-kura preferita fi prova klinika .
English: Fatigue, weakness, pain
Maltese: Dardir, stomatite, rimettar
English: For all patients
Maltese: TA' EĊĊIPJENTI
English: Solid tumour patients: in a larger cohort of 929 patients with solid tumours (including breast cancer and ovarian cancer) predominantly treated at a dose of 50 mg/m2 every 4 weeks, the safety profile and incidence of adverse effects are comparable to those of the patients treated in the pivotal breast cancer and ovarian cancer trials.
Maltese: Pazjenti b'tumuri solidi: fi grupp akbar ta' 929 pazjent b'tumuri solidi (fosthom kanċer tas-sider u ovarju) il-biċċa l-kbira ttrattati b'doża ta' 50 mg/m2 kull 4 ġimgħat, il-profil ta' sigurtà u inċidenza ta' effetti mhux mixtieqa jistgħu jitqabblu ma' dawk ta' pazjenti ttrattati fi provi kliniċi ewlenien dwar kanċer tas-sider u tal-ovarji.
English: The infusion may be given through a peripheral vein.
Maltese: L-infużjoni tista' tingħata minn vina periferali.
English: Abdominal pain, diarrhoea, nausea, stomatitis
Maltese: Uġigħ addominali, dijarea, dardir, stomatite
English: Treatment related undesirable effects reported in ovarian cancer clinical trials (50 mg/m2 every 4 weeks) (Caelyx-treated patients) by severity, MedDRA system organ class and preferred term
Maltese: Effetti mhux mixtieqa relatati mat-trattament rappurtati fi provi kliniċi tal-kanċer ovarju (50 mg/m kull 4 ġimgħat) (pazjenti ttrattati b'Caelyx) skont is-severità, sistema tal-klassi tal-organi MedDRA u terminu preferut Komuni ħafna (≥ 1/10); Komuni (≥ 1/100, < 1/10);
English: During repeat dose toxicology studies in dogs, an acute response characterised by hypotension, pale mucous membranes, salivation, emesis and periods of hyperactivity followed by hypoactivity and lethargy was observed following administration of pegylated liposomes (placebo).
Maltese: Waqt studji ta' tossikoloġija ta' dożi ripetuti fil-klieb, ripons akut ikkaratteriżat minn pressjoni baxxa, riti mukożi pallidi, salivazzjoni, emeżi u perijodi ta' iperattività segwiti minn attività mnaqqsa u letarġija ġew innutati wara l-użu ta' liposomi pegilati (plaċebo).
English: Scrotal erythema
Maltese: KONKLUŻJONIJIET XJENTIFIĊI
English: No clinically significant increases in serum creatinine were reported.
Maltese: L-ebda żieda klinikament sinifikanti ta' kreatinina fis-serum ma ġiet irrappurtata.
English: Caelyx is indicated: - As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
Maltese: Caelyx huwa indikat għal: - Monoterapija għal pazjenti b'kanċer tas-sider metastatiku, meta jkun hemm riskju kardijaku akbar.
English: Back pain, myalgia
Maltese: Uġigħ fid-dahar, majalġja
English: Leukopaenia is the most frequent undesirable effect experienced with Caelyx in this population; neutropaenia, anaemia and thrombocytopaenia have been observed.
Maltese: Lewkopenja hija l-effett mhux mixtieq l-iżjed frekwenti li ġarrbet din il-popolazzjoni b'Caelyx; newtropenja, anemija u trombocitopenja ġew osservati.
English: Of the 418 patients treated with Caelyx 50 mg/m2/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of > 400 mg/m2, an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin.
Maltese: Mill-418-il pazjent ittrattati b'Caelyx 50 mg/m2/ċiklu u li kellhom kejl ta' linja bażika ta' frazzjoni tal-ħruġ ventrikolari tax-xellug (LVEF) u almenu kejl wieħed ta' wara l-kura mkejjel b'skan MUGA, 88 pazjent kellhom doża kumulattiva ta' anthracycline ta' > 400 mg/m2, livell ta' esponiment assoċjat ma' riskju akbar ta' tossiċità kardjovaskolari b'doxorubicin konvenzjonali. 13 biss minn dawn it-88 pazjent (15 %) kellhom mill-anqas tibdil wieħed klinikament sinifikanti fil-valur tal-LVEF tagħhom, definit bħala valur LVEF anqas minn 45 % jew tnaqqis ta' mill-anqas 20 punt mill-linja bażika.
English: Clinically significant laboratory abnormalities frequently ( 5%) occurred including increases in alkaline phosphatase; AST and bilirubin which were believed to be related to the underlying disease and not Caelyx.
Maltese: Anormalitajiet frekwenti tal-laboratorju klinikament sinifikanti ( 5 %) li seħħew kienu jinkludu żidiet f'alkaline phosphatase;
English: AIDS-related KS program Clinical studies on AIDS-KS patients treated at 20 mg/m2 with Caelyx show that myelosuppression was the most frequent undesirable effect considered related to Caelyx occurring very commonly (in approximately one-half of the patients).
Maltese: Programm ta' KS relatat ma' AIDS Studji kliniċi fuq pazjenti b‘AIDS-KS ittrattati b'20 mg/m2 ta'Caelyx juru li l-majelosoppressjoni kien l-effett mhux mixtieq l-iżjed frekwenti meqjuż li kien relatat ma'Caelyx li seħħ l-aktar (madwar, nofs il-pazjenti).
English: It is recommended that the Caelyx infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose to achieve further dilution and minimise the risk of thrombosis and extravasation.
Maltese: Huwa rakkomandat li l-pajp tal-infużjoni ta' Caelyx jitqabbad mill-port tal-ġenb ta' infużjoni fil-vina ta' 5 % (50 mg/ml) glucose biex tiġi dilwita aktar u biex jonqos ir-riskju ta' trombożi u ta' emorraġija f'xi tessuti.
English: Adverse drug reactions identified during the post-marketing experience with Caelyx are described in Table 9.
Maltese: Reazzjonijiet avversi għall-mediċina identifikati matul l-esperjenza ta' wara t-tqegħid fis-suq b'Caelyx ġew deskritti f'Tabella 9.
English: Stomatitis has been reported in patients receiving continuous infusions of conventional doxorubicin hydrochloride and was frequently reported in patients receiving Caelyx.
Maltese: Stomatite ġiet irrapurtata f'pazjenti li kienu qed jieħdu trattament kontinwu b'doxorubicin hydrochloride konvenzjonali u ġiet rappurtata spiss f'pazjenti li kienu qed jieħdu Caelyx.
English: Neuralgia, peripheral neuropathy, neuropathy
Maltese: Nevralġja, newropatija periferali, newropatija
English: These effects were mostly mild, with severe (grade 3) cases reported in 17%-19.5%.
Maltese: Fil-biċċa l-kbira dawn l-effetti kienu ħfief, b'17 % - 19.5 % tal-każi rappurtati gravi (grad 3).
English: A phase III randomised study of Caelyx versus doxorubicin in patients with metastatic breast cancer was completed in 509 patients.
Maltese: III ta' Caelyx versus doxorubicin f'pazjenti b'kanċer tas-sider metastatiku tlesta f'509 pazjent.
English: Contact your doctor immediately if: - you get reddening painful skin on your hands and feet; - you get painful reddening of the skin and/or blisters on the body or in the mouth; - you get heart problems; - you get mouth sores; - you develop a fever or any other sign of an infection; - you get sudden shortness of breath or sharp chest pain that may worsen with deep breathing or coughing; - you get swelling, warmth, or tenderness in the soft tissues of your leg, sometimes with pain which gets worse when you stand or walk.
Maltese: Għarraf minnufih lit-tabib tiegħek jekk: - ikollok uġigħ u ħmura tal-ġilda f'idejk u saqajk; - ikollok ħmura b'uġigħ tal-ġilda u/jew infafet ma' ġismek jew f'ħalqek; - jaqbduk problemi tal-qalb; - jaqbduk xi selħiet f'ħalqek; - jaqbdek id-deni jew xi sinjal ieħor ta' infezzjoni; - jaqbdek qtugħ ta' nifs f'daqqa jew uġigħ f'sidrek li jista' jaggrava meta tieħu nifs fil-fond jew tisgħol; - it-tessuti rotob ta' saqajk jintefħu, jisħnu jew isiru teneri, kultant b'uġigħ li jaggrava meta tkun bil-wieqfa jew timxi.
English: Cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to Caelyx or those receiving a cumulative Caelyx dose greater than 720 mg/m2 (see section 4.4).
Maltese: Każijiet ta' kanċer orali sekondarju ġew rapportati f'pazjenti b'esponiment fuq perjodu ta' żmien twil (aktar minn sena) għal Caelyx jew dawk li rċevew doża kumulattiva ta' aktar minn 720 mg/m2 ta' Caelyx (ara sezzjoni 4.4).
English: Reproductive system and breast disorders Common
Maltese: Disturbi fis-sistema riproduttiva u fissider
English: Vascular disorders common vasodilatation
Maltese: Disturbi vaskulari komuni twessiegħ tal-vażi
English: The median TTP was 6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the Caelyx plus bortezomib combination therapy patients.
Maltese: It-TTP medjan kien 6.5 xhur għall-pazjenti fuq monoterapija b'bortezomib meta mqabbel ma' 9.3 xhur għall-pazjenti fuq terapija kombinata b'Caelyx u bortezomib.
English: Pyrexia
Maltese: Ċitotossiku
English: 45.2-98.5 hours).
Maltese: 71.5 siegħa (medda 45.2 - 98.5 siegħa).
English: * for more information on bortezomib dosing and dosage adjustment, see the SPC for bortezomib
Maltese: *għal aktar informazzjoni dwar l-aġġustamenti fid-dożi u dożaġġi ta' bortezomib, ara l-SKP ta' bortezomib
English: Abdominal pain, dyspepsia, mouth ulceration
Maltese: Uġigħ addominali, stitikezza, dijarea, dispepsja, ulċeri fil-ħalq
English: Caelyx should only be administered under the supervision of a qualified oncologist specialised in the administration of cytotoxic agents.
Maltese: Caelyx għandu jingħata biss taħt superviżjoni minn onkologu kwalifikat speċjaliżżat fl-għoti ta' sustanzi ċitotossiċi.
English: Caelyx is administered at 30 mg/m² on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion.
Maltese: Majeloma multipla Caelyx jingħata b'30 mg/m2 f'jum 4 tar-reġimen ta' 3 ġimgħat b'bortezomib bħala infużjoni ta' siegħa mogħtija eżattament wara l-infużjoni ta' bortezomib.
English: In the pivotal trial in patients with ovarian cancer treated at a dose of 50 mg/m myelosuppression was generally mild to moderate, reversible, and was not associated with episodes of neutropaenic infection or sepsis.
Maltese: Fil-prova ewlenija f'pazjenti b'kanċer ovarju li ħadu trattament b'doża ta' 50 mg/m2, il-majelosoppressjoni kienet ġeneralment ħafifa jew moderata, reversibbli u ma kinetx marbuta ma' episodji ta' infezzjoni newtropenika jew sepsis.
English: Constipation, diarrhoea, nausea, stomatitis, vomiting
Maltese: Stitikezza, dijarea, dardir, stomatite, rimettar
English: DO NOT USE INTERCHANGEABLY WITH OTHER FORMULATIONS OF DOXORUBICIN HYDROCHLORIDE.
Maltese: TIBDLUX MA' FORMULAZZJONIJIET OĦRAJN TA' DOXORUBICIN HYDROCHLORIDE.
English: CIOMS III AE by body system Ovarian cancer All severities n=512
Maltese: Kanċer ovarju Severitajiet kollha n=512
English: Studies in rabbits have shown that the cardiotoxicity of Caelyx is reduced compared with conventional doxorubicin hydrochloride preparations.
Maltese: Studji fil-fniek urew illi l-kardjotossiċità ta'Caelyx hi mnaqqsa meta mqabbla ma' taħlitiet konvenzjonali ta' doxorubicin hydrochloride.
English: If the patient experiences early symptoms or signs of infusion reaction (see sections 4.4 and 4.8), immediately discontinue the infusion, give appropriate premedications (antihistamine and/or short acting corticosteroid) and restart at a slower rate.
Maltese: Jekk il-pazjent ikollu sintomi jew sinjali ta' reazzjoni għall-infużjoni bikrin (ara sezzjonijiet 4.4 u 4.8), waqqaf l-infużjoni immedjatament, agħti premedikamenti xierqa (anti-istaminiċi u/jew kortikosterojdi li jaħdmu fuq żmien qasir) u erġa' ibda t-trattament b'rata mnaqqsa.
English: Reduction in haemoglobin and platelets were less frequently (< 5%) reported.
Maltese: Tnaqqis ta' emoglobulina u plejtlets kien rappurtat b'mod anqas frekwenti (< 5 %).
English: 5 How to store Caelyx Contents of the pack and other information
Maltese: Kif jidher Caelyx u l-kontenut tal-pakkett
English: Exercise caution in the concomitant use of medicinal products known to interact with standard doxorubicin hydrochloride.
Maltese: Oqgħod attent meta jintuża flimkien ma' prodotti mediċinali magħrufa li ma jaqblux ma'doxorubicin hydrochloride standard.
English: Stomatitis was reported more frequently in the combination therapy group (16%) than in the monotherapy group (3%), and most cases were grade 2 or less in severity.
Maltese: Stomatite kienet irrappurtata b'mod aktar frekwenti fil-grupp b'terapija kombinata (16 %) milli fil-grupp b'monoterapija (3 %), u fil-parti l-kbira, l-każijiet kellhom severità ta' grad 2 jew anqas.
English: Nausea, diarrhoea, vomiting, stomatitis
Maltese: Dardir, dijarea, rimettar, stitikezza, stomatite
English: Paediatric population The experience in children is limited.
Maltese: L-esperjenza fit-tfal hija limitata.
English: This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.
Maltese: Dan probabliment huwa ir-riżultat tal-interkalar ta' anthracycline bejn il-pari ta' bażijiet ħdejn xulxin tal-elika doppja tad-DNA u b'hekk iżommu milli tissepara biex titkattar.
English: Caelyx exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin hydrochloride.
Maltese: Caelyx għandu karatteristiċi farmakokinetiċi uniċi u m'għandux jingħata bħala sostitut ta' formulazzjonijiet oħra ta' doxorubicin hydrochloride.
English: Nausea, stomatitis, vomiting, abdominal pain, diarrhoea
Maltese: Dardir, stomatite, rimettar, uġigħ addominali, dijarea
English: If tolerated, the infusion was completed over the next hour for a total infusion time of 90 minutes.
Maltese: Jekk tkun tollerata, l-infużjoni titlesta fis-siegħa li jmiss b'ħin ta' infużjoni totali ta' 90 minuta.
English: Grade 1 (painless ulcers, erythema, or mild soreness)
Maltese: Grad 1 (ulċeri li ma jweġġgħux, ħmura talġilda, jew selħa ħafifa)
English: Skin and subcutaneous tissue disorders common alopecia, rash uncommon palmar-plantar erythrodysesthesia (PPE) General disorders and administration site conditions common asthenia, fever, infusion-associated acute reactions
Maltese: Disturbi fil-ġilda u fit-tessuti ta' taħt il-ġilda komuni alopeċja, raxx mhux komuni eritrodisestesija ta' palmar-plantar (PPEpalmar-plantar erythrodysesthesia) Disturbi ġenerali u kondizzjonijiet ta' mnejn jingħata komuni astenja, deni, reazzjonijiet akuti tal-infużjoni
English: The full EPAR for Rivastigmine Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Rivastigmine Sandoz is a medicine containing the active substance rivastigmine.
Maltese: Rivastigmine Sandoz huwa mediċina li fiha s-sustanza attiva rivastigmina.
English: Rivastigmine Sandoz has been studied in three main studies involving 2,126 patients with mild to moderately severe Alzheimer's disease.
Maltese: Rivastigmine Sandoz ġie studjat fi tliet studji ewlenin li involvew 2,126 pazjent bil-marda ta' Alzheimer minn moderata għal gravi.
English: The active substance in Rivastigmine Sandoz, rivastigmine, is an antidementia medicine.
Maltese: Is-sustanza attiva f'Rivastigmine Sandoz, ir-rivastigmina, hija mediċina kontra d-dimenzja.
English: For the global score, patients taking Rivastigmine Sandoz had an increase in symptoms of 4.1 points, compared with 4.4 in those taking placebo.
Maltese: Kwantu għall-punteġġ globali, il-pazjenti ttrattati b'Rivastigmine Sandoz kellhom żieda fis-sintomi ta' 4.1 punti apparagun ma' 4.4 punti rreġistrati fil-pazjenti ttrattati bi plaċebo.
English: An additional study in 27 patients was used to show that Rivastigmine Sandoz capsules and oral solution produced similar levels of the active substance in the blood.
Maltese: Sar studju addizzjonali ieħor fuq 27 pazjent biex juri li l-kapsuli u s-soluzzjoni orali ta' Rivastigmine Sandoz ipproduċew livelli simili tas-sustanza attiva fid-demm.
English: This is a summary of the European public assessment report (EPAR) for Rivastigmine Sandoz.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Rivastigmine Sandoz.
English: In the three studies of Rivastigmine Sandoz in patients with Alzheimer's dementia, patients taking doses of Rivastigmine Sandoz between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance.
Maltese: Fit-tliet studji li saru dwar Rivastigmine Sandoz fuq pazjenti bid-dimenzja ta' Alzheimer, il-pazjenti li ħadu dożi ta' Rivastigmine Sandoz ta' bejn 6 u 9 mg kuljum kellhom żieda medja fis-sintomi konjittivi ta' 0.2 punti, mill-valur inizjali ta' 22.9 punti fil-bidu tal-istudju.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine Sandoz on 11 December 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Rivastigmine Sandoz valida flUnjoni Ewropea kollha fil-11 ta' Diċembru 2009.
English: Rivastigmine Sandoz was more effective than placebo at controlling symptoms.
Maltese: Rivastigmine Sandoz kien aktar effikaċi mill-plaċebo fil-kontroll tas-sintomi.
English: The patients with dementia due to Parkinson's disease taking Rivastigmine Sandoz capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points.
Maltese: Il-pazjenti b'dimenzja kkaġunata mill-marda ta' Parkinson li ġew ittrattati bil-kapsuli ta' Rivastigmine Sandoz urew titjib fis-sintomi konjittivi ta' 2.1 punti apparagun mat-taħżin ta' 0.7 punti rreġistrat filpazjenti li ngħataw plaċebo, minn valur inizjali ta' madwar 24 punt.
English: Rivastigmine Sandoz was also studied in 541 patients with dementia due to Parkinson's disease.
Maltese: Sandoz ġie studjat ukoll f'541 pazjent b'dimenzja kkaġunata mill-marda ta' Parkinson.
English: Overall, the most common side effects (seen in more than 1 patient in 10) include nausea (feeling sick, seen in 38 patients in 100) and vomiting (seen in 23 patients in 100), particularly during the phase when the dose of Rivastigmine Sandoz is being increased.
Maltese: Kollox ma' kollox, l-effetti sekondarji l-aktar komuni (li dehru f'aktar minn pazjent 1 minn 10) jinkludu nawżja (dardir, li dehru fi 38 pazjent minn 100) u remettar (li dehru fi 23 pazjent minn 100), partikolarment matul il-fażi li fiha jkun qed jiżdied id-dożaġġ ta' Rivastigmine Sandoz.
English: Rivastigmine Sandoz is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Maltese: Rivastigmine Sandoz jintuża fil-kura ta' pazjenti bid-dimenzja ta' Alzheimer minn ħafifa għal moderatament gravi, diżordni progressiva tal-moħħ li bil-mod il-mod taffettwa l-memorja, l-abbiltà intellettwali u l-imġiba.
English: What is Rivastigmine Sandoz?
Maltese: X'inhu Rivastigmine Sandoz?
English: The CHMP concluded that Rivastigmine Sandoz has a modest effectiveness in treating the symptoms of Alzheimer's dementia, although this does reflect an important benefit in some patients.
Maltese: Is-CHMP ikkonkluda li Rivastigmine Sandoz għandu effikaċja moderata fit-trattament tas-sintomi taddimenzja ta' Alzheimer, għad illi dan tassew jirrappreżenta benefiċċju importanti għal uħud millpazjenti.
English: Rivastigmine Sandoz is also used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Maltese: Rivastigmine Sandoz jintuża wkoll għat-trattament tad-dimenzja minn ħafifa għal moderatament gravi f'pazjenti morda bil-Parkinson.
English: This authorisation was based on the authorisation granted to Exelon in 1998 (‘informed consent').
Maltese: Din l-awtorizzazzjoni hija bbażata fuq l-awtorizzazzjoni mogħtija lil Exelon fl-1998 (‘kunsens infurmat').
English: The Committee initially concluded that for the treatment of dementia due to Parkinson's disease, Rivastigmine Sandoz's benefits did not outweigh its risks.
Maltese: Għall-ewwel il-Kumitat kien ikkonkluda li fit-trattament tad-dimenzja kkaġunata mill-marda ta' Parkinson, il-benefiċċji ta' Rivastigmine Sandoz ma kinux ogħla mir-riskji tiegħu.
English: Other information about Rivastigmine Sandoz
Maltese: Aktar tagħrif dwar Rivastigmine Sandoz
English: For the full list of all side effects reported with Rivastigmine Sandoz, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji rrapportati bl-użu ta' Rivastigmine Sandoz, ara l-fuljett ta' tagħrif.
English: By blocking these enzymes, Rivastigmine Sandoz allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.
Maltese: Billi jimblokka dawn l-enzimi, Rivastigmine Sandoz jippermetti żieda fil-livelli tal-aċetilkolina fil-moħħ, u b'hekk jgħin fit-tnaqqis tassintomi tad-dimenzja tat-tip Alzheimer u tad-dimenzja kkaġunata mill-marda ta' Parkinson.
English: Why has Rivastigmine Sandoz been approved?
Maltese: Għaliex ġie approvat Rivastigmine Sandoz?
English: Treatment with Rivastigmine Sandoz should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease.
Maltese: It-trattament b'Rivastigmine Sandoz għandu jinbeda u jiġi mmonitorjat minn tabib li jkollu l-esperjenza fid-dijanjożi u fit-trattament tal-marda ta' Alzheimer jew fid-dimenzja f'pazjenti bil-marda ta' Parkinson.
English: What is the risk associated with Rivastigmine Sandoz?
Maltese: Għal xiex jintuża Rivastigmine Sandoz?
English: 4.6 Adverse Reactions (frequency and seriousness)
Maltese: 4.6 Effetti mhux mixtieqa (frekwenza u gravità)
English: II.E.2 Identification and assay of active ingredients
Maltese: II.E.2 Identifikazzjoni u stima tas-sustanza attiva
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis Influenza H5N6
Maltese: VETERINARJU Nobilis Influenza H5N6
English: Glycine
Maltese: Glajċin
English: Pack sizes:
Maltese: Żmien ta' Tiżmim:
English: Liquid light paraffin 234.8 mg/0.5 ml
Maltese: Paraffina likwida ħafifa 234.8mg/0.5ml
English: Adjuvant: Liquid light paraffin 234.8 mg/0.5 ml
Maltese: Adjuvant Paraffina likwida ħafifa 234.8mg/0.5ml
English: Liquid light paraffin Polysorbate 80
Maltese: Paraffina likwida ħafifa Polisorbejt 80
English: BATCH NUMBER <Lot> {number}
Maltese: NUMRU TAL-LOTT Lott {numru}
English: From 8-14 days old: 0.25 ml subcutaneously
Maltese: Minn 8 sa 14 -il ġurnata: 0.25ml taħt il-ġilda.